BALPHARMA

Bal Pharma Share Price

₹97.48 +3.32 (3.53%)

22 Feb, 2025 21:42

SIP TrendupStart SIP in BALPHARMA

Start SIP

Performance

  • Low
  • ₹95
  • High
  • ₹98
  • 52 Week Low
  • ₹89
  • 52 Week High
  • ₹158
  • Open Price₹95
  • Previous Close₹94
  • Volume12,686

Investment Returns

  • Over 1 Month -16.73%
  • Over 3 Month -25.52%
  • Over 6 Month -15.15%
  • Over 1 Year -18.29%
SIP Lightning

Smart Investing Starts Here Start SIP with Bal Pharma for Steady Growth!

Invest Now

Bal Pharma Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 21.4
  • PEG Ratio
  • 0.2
  • Market Cap Cr
  • 155
  • P/B Ratio
  • 2.3
  • Average True Range
  • 6.11
  • EPS
  • 4.56
  • Dividend Yield
  • 1.2
  • MACD Signal
  • -4.85
  • RSI
  • 39.16
  • MFI
  • 28.77

Bal Pharma Financials

Bal Pharma Technicals

EMA & SMA

Current Price
₹97.48
+ 3.32 (3.53%)
pointer
  • stock-down_img
  • Bullish Moving Average 2
  • stock-up_img
  • Bearish Moving Average 14
  • 20 Day
  • ₹102.82
  • 50 Day
  • ₹110.62
  • 100 Day
  • ₹115.84
  • 200 Day
  • ₹116.58

Resistance and Support

96.77 Pivot Speed
  • R3 101.72
  • R2 99.83
  • R1 98.66
  • S1 95.60
  • S2 93.71
  • S3 92.54

What's your outlook on Bal Pharma?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Bal Pharma has an operating revenue of Rs. 315.83 Cr. on a trailing 12-month basis. An annual revenue growth of 12% is good, Pre-tax margin of 3% needs improvement, ROE of 10% is good. The company has a debt to equity of 52%, which is bit higher. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 30 which is a POOR score indicating inconsistency in earnings, a RS Rating of 24 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at E which indicates heavy supply, Group Rank of 67 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of D is close to being the worst. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Bal Pharma Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-02-13 Quarterly Results & Fund Raising
2024-11-14 Quarterly Results
2024-08-12 Quarterly Results, ESOP & A.G.M.
2024-05-28 Audited Results & Final Dividend
2024-02-12 Quarterly Results

Bal Pharma F&O

Bal Pharma Shareholding Pattern

50.86%
0.14%
32.57%
16.43%

About Bal Pharma

  • NSE Symbol
  • BALPHARMA
  • BSE Symbol
  • 524824
  • Managing Director
  • Mr. Shailesh D Siroya
  • ISIN
  • INE083D01012

Similar Stocks to Bal Pharma

Bal Pharma FAQs

Bal Pharma share price is ₹97 As on 22 February, 2025 | 21:28

The Market Cap of Bal Pharma is ₹155.2 Cr As on 22 February, 2025 | 21:28

The P/E ratio of Bal Pharma is 21.4 As on 22 February, 2025 | 21:28

The PB ratio of Bal Pharma is 2.3 As on 22 February, 2025 | 21:28

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23